Approved January 1998
Non-small cell lung cancer
Cancer & Oncology
QLT PhotoTherapeutics' light-activated drug Photofrin (porfimer sodium) was approved for injection in treating early-stage, microinvasive lung cancer. It is approved for use in patients with microinvasive endobronchial non-small cell lung cancer at an early stage, for whom surgery and radiotherapy are not indicated.
The Photofrin drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.